Grifols (LTS:0RDU) Total Liabilities : €12,798 Mil (As of Dec. 2024)

View and export this data going back to 2009. Start your Free Trial

What is Grifols Total Liabilities?

Grifols's Total Liabilities for the quarter that ended in Dec. 2024 was €12,798 Mil.

Grifols's quarterly Total Liabilities declined from Jun. 2024 (€13,996.18 Mil) to Sep. 2024 (€12,288.58 Mil) but then increased from Sep. 2024 (€12,288.58 Mil) to Dec. 2024 (€12,798.22 Mil).

Grifols's annual Total Liabilities increased from Dec. 2022 (€13,253.46 Mil) to Dec. 2023 (€13,478.41 Mil) but then declined from Dec. 2023 (€13,478.41 Mil) to Dec. 2024 (€12,798.22 Mil).

Grifols Total Liabilities Historical Data

The historical data trend for Grifols's Total Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Grifols Total Liabilities Chart

Grifols Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Total Liabilities

Get a 7-Day Free Trial

8,554.72

11,916.74

13,253.46

13,478.41

12,798.22

Grifols Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Dec21	Jun22	Sep22	Dec22	Jun23	Sep23	Dec23	Jun24	Sep24	Dec24
Total Liabilities	Get a 7-Day Free Trial															13,495.81	13,478.41	13,996.18	12,288.58	12,798.22

Grifols Total Liabilities Calculation

Total Liabilities are the liabilities that the company has to pay others. It is a part of the balance sheet of a company that shareholders do not own, and would be obligated to pay back if the company liquidated.

Grifols's Total Liabilities for the fiscal year that ended in Dec. 2024 is calculated as

Total Liabilities	=	Total Current Liabilities	+	Total Noncurrent Liabilities
	=	Total Current Liabilities	+	(Long-Term Debt & Capital Lease Obligation	+	Other Long-Term Liabilities
	=	2156.146	+	(9445.958	+	170.464
	+	NonCurrent Deferred Liabilities	+	PensionAndRetirementBenefit	+	NonCurrent Deferred Income Tax)
	+	1025.648	+	0	+	0)
	=	12,798

Total Liabilities	=	Total Assets (A: Dec. 2024 )	-	Total Equity (A: Dec. 2024 )
	=	21405.241	-	8607.025
	=	12,798

Grifols's Total Liabilities for the quarter that ended in Dec. 2024 is calculated as

Total Liabilities	=	Total Current Liabilities	+	Total Noncurrent Liabilities
	=	Total Current Liabilities	+	(Long-Term Debt & Capital Lease Obligation	+	Other Long-Term Liabilities
	=	2156.146	+	(9445.958	+	170.464
	+	NonCurrent Deferred Liabilities	+	PensionAndRetirementBenefit	+	NonCurrent Deferred Income Tax)
	+	1025.648	+	0	+	0)
	=	12,798

Total Liabilities	=	Total Assets (Q: Dec. 2024 )	-	Total Equity (Q: Dec. 2024 )
	=	21405.241	-	8607.025
	=	12,798

Grifols Total Liabilities Related Terms

Thank you for viewing the detailed overview of Grifols's Total Liabilities provided by GuruFocus.com. Please click on the following links to see related term pages.

Grifols Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Grifols SA (LTS:0RDU) » Definitions » Total Liabilities

Comparable Companies

Traded in Other Exchanges

GIKLY:USA GIFOF:USA GIFLF:USA GRFS:USA 1GRF:Italy GRFe:UK GRFPe:UK 0RDV:UK GRF.P:Spain GRF:Spain OZTA:Germany GRF:Austria

Address

Avinguda de la Generalitat, 152-158, Parc de Negocis Can Sant Joan, Sant Cugat del Valles, Barcelona, ESP, 08174

Website

https://www.grifols.com

Grifols SA one of is global specialty plasma therapeutics companies developing, manufacturing and distributing a broad range of biological medicines based on plasma derived proteins. Plasma derivatives are proteins found in human plasma, which once isolated and purified, have therapeutic value. These protein-based therapies extend and enhance the lives of individuals who suffer from chronic and acute, often life-threatening, conditions, including primary and secondary immunological deficiencies, Chronic Inflammatory Demyelinating Polyneuropathy, immune-mediated ITP. Products and services are used to diagnose and treat patients with hemophilia, immune deficiencies, infectious diseases and a range of other medical conditions. Majority of revenue is from USA.

Grifols Headlines

No Headlines